Careers  |  Sign In  |  Register

FDA Approves Two Drugs for Treatment of Fatal Lung Disease

According to The New York Times, the FDA has approved a pair of drugs that can slow the progression of idiopathic pulmonary fibrosis. Roche’s Esbriet and Boehringer Ingelheim’s Ofev do not cure the disease, but can slow the rate at which it impairs lung function. Esbriet will cost patients in the US roughly $94,000 annually, two to three times more than its selling price in Canada and Europe, while Boehringer Ingelheim declined to disclose the price of Ofev until its release.

Read it in The New York Times.